| Drug General Information |
| Drug ID |
D07QMC
|
| Former ID |
DNC003626
|
| Drug Name |
3-Benzimidazol-2-ylhydroquinolin-2-one
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H11N3O
|
| Canonical SMILES |
C1=CC=C2C(=C1)NC(=C3C=C4C=CC=CC4=NC3=O)N2
|
| InChI |
1S/C16H11N3O/c20-16-11(9-10-5-1-2-6-12(10)19-16)15-17-13-7-3-4-8-14(13)18-15/h1-9,17-18H
|
| InChIKey |
VAAMBTAFTGILMX-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
| Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04010:MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathwayP00005:Angiogenesis
|
|
PDGF signaling pathwayP00005:Angiogenesis
|
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkptp1bpathway:Signaling events mediated by PTP1B
|
|
S1P3 pathway
|
|
Nectin adhesion pathway
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
PDGFR-beta signaling pathway
|
|
Validated targets of C-MYC transcriptional repression
|
|
PDGF receptor signaling networkglypican_1pathway:Glypican 1 network
|
|
Syndecan-4-mediated signaling events
|
|
N-cadherin signaling events
|
|
FGF signaling pathway
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP51:Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
Osteoblast Signaling
|
|
PIP3 activates AKT signaling
|
|
PDGF Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Signaling by PDGFWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Mesodermal Commitment Pathway
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
| References |
| REF 1 | J Med Chem. 2009 Jan 22;52(2):278-92.Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. |
|---|
